Condition: Geographic Atrophy Secondary to Age-related Macular Degeneration · Sponsor: Complement Therapeutics
This is a clinical study to evaluate the safety, tolerability and efficacy of CTx001, administered via a single subretinal injection, for GA (secondary to AMD). Safety and efficacy will be measured at regular intervals for 2 years after which long-term safety will be assessed annually for up to 5 years.
This description comes directly from the study's public registry record.
Muhammad Ali Memon · clinicaltrials@complementtx.com
Always discuss trial participation with your own doctor first.
| Midwest Eye Institute | Carmel, Indiana, United States | Recruiting |
| Sierra Eye Associates | Reno, Nevada, United States | Recruiting |
| Retina Foundation of the Southwest | Dallas, Texas, United States | Recruiting |
| Gundersen Health System | La Crosse, Wisconsin, United States | Recruiting |
| The Retina Clinic London | London, London, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07392255